Eosinophilic myeloid disorders.

Area of Science:

• Hematology
• Oncology
• Molecular Pathology

Background:

• Mutations in platelet-derived growth factor receptors alpha and beta (PDGFRA and PDGFRB) are therapeutically relevant in clonal eosinophilia.
• Despite advances, over 50% of patients are diagnosed with idiopathic disease, with others having clonal myeloid or lymphocytic disorders.
• The World Health Organization classification recognizes semi-molecular subgroups for eosinophilic myeloid disorders, including those with PDGFRA, PDGFRB, or FGFR1 abnormalities.

Purpose of the Study:

• To review the impact of PDGFRA and PDGFRB mutations on the evaluation and treatment of clonal eosinophilia.
• To discuss the current classification of eosinophilic myeloid disorders.
• To highlight the ongoing challenge of identifying tyrosine kinase-responsive molecular lesions in unexplained clonal eosinophilia.

Main Methods:

• Review of current literature and clinical classifications.
• Analysis of diagnostic categories for clonal eosinophilia.
• Discussion of molecular targets and pathobiology.

Main Results:

• PDGFRA/PDGFRB mutations have significantly altered the diagnostic and therapeutic landscape for clonal eosinophilia.
• The classification system now incorporates molecular abnormalities, distinguishing specific subgroups.
• A significant proportion of patients still lack a clear molecular diagnosis, presenting a therapeutic challenge.

Conclusions:

• Understanding PDGFRA/PDGFRB mutations is crucial for managing clonal eosinophilia.
• Further research is needed to identify molecular drivers in idiopathic and unexplained cases.
• Targeting tyrosine kinases remains a key strategy for treating specific eosinophilic disorders.